Indivumed Deepens Collaboration with University of Rochester for Innovative Cancer Therapies

Strengthening Cancer Research Collaboration: Indivumed and URMC

In a significant step towards improving cancer therapies, Indivumed has announced an expanded partnership with the University of Rochester Medical Center (URMC) and its renowned Wilmot Cancer Institute. This collaboration is all about enhancing precision oncology through the combined expertise of both institutions, focusing on patient-centered development of novel cancer treatments.

The Necessity for Innovative Therapies

With cancer remaining one of the leading causes of mortality worldwide, the need for innovative and effective treatments has never been greater. Indivumed aims to leverage its established methodology in standardized tissue and clinical data collection to accelerate the development of therapies for patients with medical needs that are currently unmet. Through this partnership, both institutions acknowledge the urgent requirement to provide personalized treatment options.

Core Components of the Partnership

One of the core aspects of this collaboration is the meticulous collection and curation of surgical tissue samples alongside extensive clinical data. URMC plays a pivotal role in obtaining and processing high-quality bioprobes and clinical patient data following Indivumed’s strict standard operating procedures (SOPs). A noteworthy feature of this collaboration is the reduction of ischemia time to under ten minutes, which is crucial in ensuring the integrity and quality of samples for further analysis.

The main goal is to develop well-characterized, patient-derived tumor models (PDTMs) from these samples. These cellular models will aid in identifying, validating, and developing new molecular targets in cancer therapy, thereby expediting the pharmaceutical development process while minimizing associated risks.